Coherus Oncology CHRS
NASDAQ CHRS
$0.75 +0.00 (+0.56%)
As of: Nov 6, 2026 · 9:54 AM EST

Coherus Oncology (CHRS) Notes Payables (2013 - 2021)

Updated

Coherus Oncology's Notes Payables was $80.98 million in Q3 2021, up 0.5% from the prior quarter.

Analysis

Coherus Oncology (CHRS) Notes Payables (2013 - 2021) Analysis & Trends

At the end of FY2013, Notes Payables at Coherus Oncology came in at $3.09 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,221.54 Bn 1,195.15 Bn 20.46 Bn
2 Johnson & Johnson 650.21 Bn 570.07 Bn 17.30 Bn
3 AbbVie 508.24 Bn 476.24 Bn 13.12 Bn
4 Merck 360.07 Bn 323.01 Bn 13.19 Bn
5 Novartis Ag 312.26 Bn 285.49 Bn -
6 Astrazeneca 285.31 Bn 259.20 Bn 13.26 Bn
7 Amgen 247.74 Bn 199.39 Bn 7.58 Bn
8 Gilead Sciences 207.12 Bn 182.22 Bn 6.73 Bn
9 Pfizer 166.13 Bn 113.48 Bn 12.56 Bn
10 Coherus Oncology 116.17 Mn -519.97 Mn 10.07 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2021 80.98 Mn
Jun 30, 2021 80.61 Mn
Mar 31, 2021 80.24 Mn
Dec 31, 2013 3.09 Mn
API Access

Coherus Oncology Notes Payables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=notes-payables&ticker=CHRS&period=max&api_key=YOUR_API_KEY